Russell Investments Boosts Stake in Ultragenyx Pharmaceutical

Institutional investor increases holding in rare disease biotech company by 599.2% in Q3

Mar. 13, 2026 at 9:54am

Got story updates? Submit your updates here. ›

Russell Investments Group Ltd. significantly increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 599.2% in the third quarter, according to a recent SEC filing. The institutional investor now owns 840,451 shares of the biopharmaceutical company's stock, representing approximately 0.87% of Ultragenyx's outstanding shares.

Why it matters

Ultragenyx is a leading rare disease biotech company focused on developing therapies for genetic disorders. Russell Investments' substantial increase in its Ultragenyx holdings suggests the firm sees strong long-term potential in the company's pipeline and commercial products.

The details

According to the SEC filing, Russell Investments bought an additional 720,256 shares of Ultragenyx in the third quarter, bringing its total position to 840,451 shares. This represents a 599.2% increase in the firm's holding of the biopharmaceutical company's stock.

  • Russell Investments increased its Ultragenyx stake in the 3rd quarter of 2026.

The players

Russell Investments Group Ltd.

An American global asset management firm that provides investment solutions to institutional and individual investors worldwide.

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

Russell Investments' substantial increase in its Ultragenyx holdings underscores the institutional investor's confidence in the rare disease biotech company's long-term growth potential as it advances its pipeline of innovative therapies.